3rd Quarter - Report
BROWNSTEIN HYATT FARBER SCHRECK, LLP for SAFE RX
Client
Income
$10,000
Expenses
—
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Alcohol and Drug Abuse ALC
Educating policy makers about anti-pilfering technology known as locking prescription vials (LPVs) Issues relating to establishing a pilot program for LPVs Issues relating to DEA's authority to regulate dispensing Schedule II-IV drugs S. 524/H.R. 953 - Comprehensive Addiction and Recovery Act of 2016 S. 2943/H.R. 4909 - National Defense Authorization Act for fiscal year 2017
| Lobbyist | Covered position, as disclosed |
|---|---|
| CATE MCCANLESS BLANKENBURG | — |
| LAURA JOHNSON BOLLIER | — |
| ALEXANDER DAHL | — |
| PETER M. GOODLOE | — |
| ELIZABETH M GORE | — |
| MARC LAMPKIN | — |
| ELIZABETH ANNE MAIER | — |
| WILLIAM MOSCHELLA | — |
| ZACHARY PFISTER | — |
| NEIL F QUINTER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.